Compare BRKR & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRKR | TGTX |
|---|---|---|
| Founded | 1960 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 8.5B |
| IPO Year | 2000 | 2008 |
| Metric | BRKR | TGTX |
|---|---|---|
| Price | $61.74 | $53.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $48.54 | ★ $49.80 |
| AVG Volume (30 Days) | 1.9M | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | 0.02 | ★ 0.12 |
| Revenue | ★ $1,895,600,000.00 | $2,785,000.00 |
| Revenue This Year | $6.30 | $49.08 |
| Revenue Next Year | $3.81 | $26.69 |
| P/E Ratio | $3,144.50 | ★ $457.29 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.53 | $25.37 |
| 52 Week High | $64.95 | $59.30 |
| Indicator | BRKR | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 51.91 |
| Support Level | $54.54 | $51.15 |
| Resistance Level | $64.18 | $58.34 |
| Average True Range (ATR) | 3.05 | 2.23 |
| MACD | -0.03 | -0.57 |
| Stochastic Oscillator | 74.63 | 36.41 |
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.